Attached files

file filename
EX-23.2 - EX-23.2 - AbCellera Biologics Inc.d68178dex232.htm
EX-23.1 - EX-23.1 - AbCellera Biologics Inc.d68178dex231.htm
EX-5.1 - EX-5.1 - AbCellera Biologics Inc.d68178dex51.htm

As filed with the Securities and Exchange Commission on December 10, 2020.

Registration No. 333-

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-1

REGISTRATION STATEMENT

Under

The Securities Act of 1933

 

 

AbCellera Biologics Inc.

(Exact name of registrant as specified in its charter)

 

 

 

British Columbia   8731   Not Applicable
(State or other jurisdiction of   (Primary Standard Industrial   (I.R.S. Employer
incorporation or organization)   Classification Code Number)   Identification Number)

AbCellera Biologics Inc.

2215 Yukon Street

Vancouver, BC V5Y 0A1

(604) 559-9005

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

The Corporation Trust Company

Corporation Trust Center

1209 Orange Street

Wilmington, DE 19801

(302) 658-7581

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Sam Zucker
Deepa M. Rich

Mitchell S. Bloom

James Xu

Goodwin Procter LLP

601 Marshall Street

Redwood City, CA 94063

(650) 752-3100

 

Joseph Garcia

Blake, Cassels & Graydon LLP

595 Burrard Street, Suite 2600 Vancouver, BC V7X 1L3

Canada

(604) 631-3300

 

Carl L. G. Hansen, Ph.D.

Andrew Booth

Tryn T. Stimart

AbCellera Biologics Inc.

2215 Yukon Street

Vancouver, BC V5Y 0A1

Canada

(604) 559-9005

  

Charles S. Kim

Kristin VanderPas

Divakar Gupta

Richard Segal

Cooley LLP

4401 Eastgate Mall

San Diego, CA 92121

(858) 550-6000

  

Shahir Guindi

Trevor Scott

Osler, Hoskin & Harcourt LLP

Suite 1700, Guinness Tower

1055 West Hastings Street

Vancouver, BC V6E 2E9

Canada

(778) 785-3000

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box.  ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☒  333-250838

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer        Accelerated Filer  
Non-Accelerated Filer        Smaller Reporting Company  
       Emerging Growth Company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Each Class of
Securities to be Registered
  Amount
to be
registered(1)
  Proposed
maximum
aggregate
offering price
per share
  Proposed
maximum
aggregate
offering price
  Amount of
registration fee(2)

Common stock, no par value per share

  1,322,500   $20.00   $26,450,000   $2,886

 

(1)

Represents only the additional number of shares being registered and includes 172,500 shares of common stock issuable upon exercise of the underwriters’ option to purchase additional shares. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-250838), as amended (the “Earlier Registration Statement”).

(2)

The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities on the Earlier Registration Statement at an aggregate offering price not to exceed $476,100,000.00, which was declared effective by the Securities and Exchange Commission on December 10, 2020. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $26,450,000 is hereby registered, which includes shares issuable upon the exercise of the underwriters’ option to purchase additional shares.

 

The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

 

 

 


Explanatory note and incorporation by reference

This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”), for the sole purpose of increasing the aggregate number of shares of common stock offered by AbCellera Biologics Inc. (the “Registrant”) by 1,322,500 shares, 172,500 of which are subject to purchase upon exercise of the underwriters’ option to purchase additional shares of the Registrant’s common stock. The contents of the Registration Statement on Form S-1, as amended (File No. 333-250838), filed by the Registrant with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act, which was declared effective by the Commission on December 10, 2020, or the Earlier Registration Statement, are incorporated by reference into this Registration Statement. The additional shares of common stock that are being registered for issuance and sale pursuant to this registration statement are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Earlier Registration Statement.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

EXHIBIT INDEX

 

Exhibit No.

  

Exhibit Index

5.1    Opinion of Blake, Cassels & Graydon LLP
23.1    Consent of KPMG LLP, Independent Registered Public Accounting Firm
23.2    Consent of Armanino LLP, Independent Registered Public Accounting Firm
23.3    Consent of Blake, Cassels & Graydon LLP (included in Exhibit 5.1)
24.1*    Power of Attorney
24.2+    Power of Attorney for John Edward Hamer

 

*

Previously filed on the signature page to the Registrant’s Registration Statement on Form S-1 (File No. 333-250838), originally filed with the Securities and Exchange Commission on November 20, 2020 and incorporated by reference herein.

+

Previously filed on the signature page to the Registrant’s Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-250838), originally filed with the Securities and Exchange Commission on December 7, 2020 and incorporated by reference herein.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vancouver, Province of British Columbia, Canada, on the 10th day of December, 2020.

 

ABCELLERA BIOLOGICS INC.
By:  

/s/ Carl L. G. Hansen

  Carl L. G. Hansen, Ph.D.
  Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-1 has been signed by the following person in the capacities and on the date indicated.

 

Signature

  

Title

  

Date

/s/ Carl L. G. Hansen

  

Chief Executive Officer and Director

(Principal Executive Officer)

   December 10, 2020
Carl L. G. Hansen, Ph.D.

/s/ Andrew Booth

  

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

   December 10, 2020
Andrew Booth

*

  

Director

   December 10, 2020
Véronique Lecault, Ph.D.

*

  

Director

   December 10, 2020
John Edward Hamer, Ph.D.

*

  

Director

   December 10, 2020
Michael Hayden, Ph.D.

*

  

Director

   December 10, 2020
John S. Montalbano

*

  

Director

   December 10, 2020
Peter Thiel

/s/ Tryn Stimart

  

Authorized Representative in the United States

   December 10, 2020
Tryn Stimart

 

*By:  

/s/ Carl L. G. Hansen, Ph.D.

  Carl L. G. Hansen, Ph.D.
  Attorney-in-fact